Dong Moon Shin, MD, FACP, FAAAS
Professor, Hematology/Oncology & Otolaryngology
Emory University School of Medicine
Frances Kelly Blomeyer Chair in Cancer Research
Emory University School of Medicine
Director, Head and Neck SPORE Program
Winship Cancer Institute of Emory University
Office: Winship Cancer Institute of Emory University
Phone: (404) 778-1947
For all patient inquiries or appointment requests, please dial (404) 778-1900. Fax patient records to (404) 778-2177.
Dr. Dong Moon Shin is the Frances Kelly Blomeyer Distinguished Endowed Chair in Cancer Research, Professor of Hematology and Medical Oncology, Professor of Otolaryngology, Professor of Biomedical Engineering, Director of the Head and Neck Cancer SPORE Program and Georgia Cancer Coalition Distinguished Scholar at Winship Cancer Institute of Emory University.
Dr. Shin is a Fellow of the American College of Physicians and a Fellow of the American Association for the Advancement of Science.
Dr. Shin has a highly successful scholar and research track record as a head and neck cancer investigator. He is a well-established, internationally and nationally recognized investigator in head and neck cancer research related to biology, biomarkers, chemoprevention, biochemoprevention, new drug discovery by nanotherapeutics, and new molecularly-based and immune-based innovative therapies.
Dr. Shin joined Winship Cancer Institute of Emory University in 2003, as Professor of Hematology and Oncology and Otolaryngology. He has played a major leadership role in several areas including the Eastern Cooperative Oncology Group, American Society of Clinical Oncology, American Association of Cancer Research at the national level in addition to Winship Cancer Institute’s Operations Committee and Associate Director of Academic Development at Winship Cancer Institute of Emory University. Prior to joining Emory, Dr. Shin graduated from Yonsei University College of Medicine, Seoul, Korea, completed Residency training in Internal Medicine at Cook County Hospital in Chicago, Illinois and trained in Medical Oncology and Research Fellowship at the University of Texas MD Anderson Cancer Center and was appointed as tenured professor at the University of Pittsburgh and MD Anderson Medical Center.
Dr. Shin has served on the editorial boards of fifteen cancer related journals and as a study section member on NCI grant review panels. He has been consecutively selected for Best Doctors in America, Top Doctors in Oncology, selected by Atlanta Magazine, and America’s Top Doctors, selected by Castle Connolly Ltd. for many years. He is a board certified physician by the American Board of Internal Medicine (Specialty) and Medical Oncology (Sub-Specialty).
Dr. Shin's scientific accomplishments are highlighted by his success in securing and maintaining highly competitive peer-reviewed funding from the NIH, ACS, FDA and other agencies through out his career.
Dr. Shin's research focus is in head, neck and lung cancers. During the past 30 years his research has been in the following areas: establishing carcinogenesis models in preclinical and clinical settings for head, neck and lung cancer; developing biomarkers in animal and human carcinogenesis for head, neck and lung cancer; developing molecular targeted prevention and therapies using epidermal growth factor receptor (EGFR) signaling pathways (i.e., EGFR monoclonal antibodies, EGFR tyrosine kinase inhibitors cyclooxygenase-2 (COX-2) inhibitors, other molecularly targeted molecules and several natural compounds; and developing novel therapeutics (clinical or translational protocols) for head and neck cancer, thymoma and mesothelioma. He is also currently focused on new drug delivery to cancer patients using nanotechnology in his research laboratory.
Dr. Shin has published over 340 peer reviewed scientific articles in journals such as The New England Journal of Medicine, The Journal of the National Cancer Institute, Cancer Research, and The Journal of Clinical Oncology. Dr. Shin's research is widely cited in thousands of studies and peer reviewed papers.
View clinical trials at Winship Cancer Institute